君实(01877.HK)急涨18%曾见59.8元新高 旗下新冠病毒中和抗体药品完成首例给药
君实生物-B(01877.HK)旗下新冠病毒中和抗体药品获批开展临床研究及完成首例给药,该股今早扭两两连吐,曾飙升37%高见59.8元,突破上月中旬所创上市高位49.7元,现造51.35元,急弹18%,成交急增至261万股,涉资1.32亿元。
君实公布,重组全人源抗SARS-CoV-2单克隆抗体注射液(项目代号:JS016)已於近日获得国家药品监督管理局批准开展I期临床研究,并已完成首例受试者给药。该研究设计是一项随机、双盲、安慰剂对照研究,目的是评价JS016在中国人群中的耐受性、安全性和药代动力学特徵及免疫原性,为JS016後续临床研究提供依据。JS016是中国最早进入临床阶段的新冠病毒中和抗体,其开发速度处於国际领先地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.